Clinical research of novel immunotherapy with PD-1 monoclonal antibody combined with activation of IFN signaling pathway in patients with pancreatic cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017665

Enrollment

Unknown

Registered

2018-08-08

Start date

2018-11-01

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

1:PD-1 monoclonal antibody combined with IFN-? treatment+Conventional chemotherapy

2:Conventional chemotherapy

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with pancreatic cancer diagnosed by clinical pathology

Exclusion criteria

Exclusion criteria: All systemic diseases such as malignant tumor history, preoperative acute and chronic infection, immune system disease, diabetes and other diseases, antiinfective therapy and immunomodulatory drugs were used to assist the antitumor treatment.

Design outcomes

Primary

Measure	Time frame
Incidence of complications;Tumor free survival time;Cumulative survival time;Expression of PD-1 in peripheral blood T cells;Expression of PD-1 in tumor associated T cells;Expression of IFN- gamma in peripheral blood T cells;Expression of IFN- gamma in tumor associated T cells;	—

Countries

China

Contacts

Public ContactZhang Mingjie

Department of Hepatobiliary and Pancreatic surgery, Huzhou Hospital, Zhejiang University School of Medicine (Huzhou Central Hospital)

zmjys001053@163.com+86 13567281638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026